Isosteviol improves cardiac function and promotes angiogenesis after myocardial infarction in rats
- 25 November 2021
- journal article
- research article
- Published by Springer Nature in Cell and tissue research
- Vol. 387 (2) , 275-285
Abstract
Isosteviol has been indicated as a cardiomyocyte protector. However, the underlying mechanism remains unclear. Thus, we sought to confirm the protective effect of isosteviol after myocardial infarction in a model of permanent coronary artery occlusion and investigate the potential proangiogenic activity in vitro and in vivo. A 4-week permanent coronary artery occlusion rat model was generated, and the protective effect of isosteviol was evaluated by echocardiographic imaging and hemodynamics assays. The coronary capillary density was tested by immunochemistry and micro-computed tomography (μCT) imaging. The effect of isosteviol on endothelial cells was determined in human umbilical vein endothelial cells (HUVECs) in vitro and Tg (kdrl: EGFP) zebrafish in vivo. We also examined the expression of related transcription factors by real-time polymerase chain reaction (RT-qPCR). Isosteviol increased ejection fraction (EF), fractional shortening (FS), cardiac systolic index (CI), maximum rate of increase of left ventricular pressure (Max dp/dt), and left ventricular systolic pressure (LVSP) by 32%, 40%, 25%, 26%, and 10%, respectively, in permanent coronary artery occlusion rats. Interestingly, it also promoted coronary capillary density by 2.5-fold. In addition, isosteviol promoted the proliferation and branching of HUVECs in vitro. It also rescued intersegmental vessel (ISV) development and improved endothelial cell proliferation by approximately fivefold (4–6) in zebrafish embryos in vivo. Isosteviol also upregulated the expression of hypoxia inducible factor-1α (HIF-1α) and vascular endothelial growth factor A (VEGFA) in zebrafish by fourfold and 3.5-fold, respectively. Our findings suggest that isosteviol is a proangiogenic agent and that this activity is related to its protective effects against myocardial ischemia. Graphical abstract After using the permanent coronary artery occlusion model, we demonstrated that isosteviol promotes angiogenesis directly and increases capillary density in myocardial ischemia rats. Isosteviol promotes angiogenesis in zebrafish in vivo and increases vascular endothelial cell proliferation in HUVECs and zebrafish. The angiogenesis activity of isosteviol may be correlated with VEGFA and HIF-1α signaling.Keywords
Funding Information
- National Natural Science Foundation of China (81903600)
- Postdoctoral Research Foundation of China (2018M643026)
- Technology Innovation Project of Foshan (2017IT100162)
- National Major Science and Technology Projects of China (2019ZX09301120)
This publication has 34 references indexed in Scilit:
- Isosteviol Sensitizes sarcKATP Channels towards Pinacidil and Potentiates Mitochondrial Uncoupling of Diazoxide in Guinea Pig Ventricular MyocytesOxidative Medicine and Cellular Longevity, 2016
- Modified VEGF targets the ischemic myocardium and promotes functional recovery after myocardial infarctionJournal of Controlled Release, 2015
- Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenaseScience Translational Medicine, 2014
- VEGF‐B‐induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heartEMBO Molecular Medicine, 2014
- Topical secretoneurin gene therapy accelerates diabetic wound healing by interaction between heparan-sulfate proteoglycans and basic FGFAngiogenesis, 2013
- High-Throughput Screening for Bioactive Molecules Using Primary Cell Culture of Transgenic Zebrafish EmbryosCell Reports, 2012
- Therapeutic angiogenesis for myocardial ischemia revisited: basic biological concepts and focus on latest clinical trialsAngiogenesis, 2011
- Genetic and cellular analyses of zebrafish atrioventricular cushion and valve developmentDevelopment, 2005
- Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trialThe Lancet, 2002
- Mechanisms of angiogenesisNature, 1997